SIGLEC15 Recombinant Monoclonal Antibody

SIGLEC15 (Sialic acid-binding Ig-like lectin 15) has emerged as a compelling target in immunology and oncology research, functioning as an immune checkpoint molecule that suppresses T cell activation. This member of the Siglec family plays a dual role in biology, regulating both immune responses and osteoclast differentiation, making it particularly relevant for studies investigating tumor immune evasion mechanisms and bone metabolism disorders.

This recombinant monoclonal antibody against human SIGLEC15, clone 1-10E5, offers researchers the reproducibility and consistency that recombinant technology provides. Because the antibody sequence is defined and produced through recombinant expression rather than traditional hybridoma methods, you can expect reliable performance across experiments and between lot numbers, supporting the reproducibility of your long-term research programs.

Functional validation demonstrates strong binding characteristics in ELISA applications, with the antibody showing robust activity against immobilized human SIGLEC15 protein. Testing revealed an EC50 range of 12.42-16.08 ng/mL, indicating high-affinity binding suitable for sensitive detection assays. The recommended working dilution range of 1:5000 to 1:50000 for ELISA provides flexibility to optimize conditions for your specific experimental setup.

Supplied as a human IgG1 isotype in a glycerol-based PBS buffer with Proclin 300 preservative, this affinity-purified antibody is ready for immediate use in your detection workflows. For researchers investigating SIGLEC15 as a therapeutic target, studying immune checkpoint biology, or exploring osteoclast function, this antibody provides a well-characterized tool for advancing your understanding of this increasingly important immunomodulatory molecule.